Case Report: Staged alteplase administration under VA-ECMO support for high-risk pulmonary embolism with severe thrombocytopenia
4 affiliations
- 1Department of Respiratory Medicine, Linyi People's Hospital
- 2Department of Radiology, Linyi People's Hospital
- 3Emergency Department, Linyi People's Hospital
- 4Respiratory Intensive Care Unit, Linyi People's Hospital
Abstract
High-risk pulmonary embolism (PE) with severe thrombocytopenia creates competing reperfusion and bleeding risks. A 28-year-old man presented with obstructive shock and central pulmonary arterial filling defects. The last documented platelet count before alteplase was 21 × 10⁹/L; platelet transfusion intervened, and the count at infusion initiation was unknown. Venoarterial extracorporeal membrane oxygenation (VA-ECMO) and hemostatic support were instituted. With increasing vasoactive requirements, the team selected bedside systemic thrombolysis after multidisciplinary consideration of surgical and catheter-based alternatives. Unfractionated heparin was paused at the first 20-mg alteplase infusion at 17:00. Arterial cannulation-site bleeding at 17:20 was treated with compression. The progress note documented that bleeding had stopped by 19:03; despite reduced vasoactive requirements, support dependence persisted. A second 20-mg infusion began at 19:25. Each stage lasted approximately 1 h. Heparin was restarted after the second infusion. Vasopressors were stopped on Day 1 and VA-ECMO was removed on Day 7. Hemoglobin fell from 150 to 117 g/L on Day 0 and reached 75 g/L on Day 8, prompting red-cell transfusion. Major bleeding could not be excluded. The patient was discharged on Day 19; Day 103 imaging showed no obvious residual pulmonary arterial filling defect. This case describes individualized decisions during multimodal care, not a validated alteplase regimen or evidence of its safety.
Related
- From bradyarrhythmia to embolism: A rare case of acute pulmonary embolism immediately after pacemaker implantation.
- Diagnostic challenge of pulmonary embolism during testosterone replacement therapy for primary hypogonadism
- Right ventricular strain analysis in acute pulmonary embolism and its role for late complications
- Mechanical Thrombectomy for Pulmonary Tumor Embolism Masquerading as Bland Pulmonary Embolism: A Case Report.
- New era of pulmonary embolism: Precision, intervention, and innovation
BibTeX
@article{kang2026case,
title = {{Case Report: Staged alteplase administration under VA-ECMO support for high-risk pulmonary embolism with severe thrombocytopenia}},
author = {Le Kang and Yanfei Lin and Shuai Wang and Xia Ji},
journal = {Frontiers in Cardiovascular Medicine},
year = {2026},
month = oct,
doi = {10.3389/fcvm.2026.1977983},
url = {https://www.frontiersin.org/articles/10.3389/fcvm.2026.1977983/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Case Report: Staged alteplase administration under VA-ECMO support for high-risk pulmonary embolism with severe thrombocytopenia
AU - Le Kang
AU - Yanfei Lin
AU - Shuai Wang
AU - Xia Ji
PY - 2026
DA - 2026/10/08
JO - Frontiers in Cardiovascular Medicine
DO - 10.3389/fcvm.2026.1977983
UR - https://www.frontiersin.org/articles/10.3389/fcvm.2026.1977983/full
AB - High-risk pulmonary embolism (PE) with severe thrombocytopenia creates competing reperfusion and bleeding risks. A 28-year-old man presented with obstructive shock and central pulmonary arterial filling defects. The last documented platelet count before alteplase was 21 × 10⁹/L; platelet transfusion intervened, and the count at infusion initiation was unknown. Venoarterial extracorporeal membrane oxygenation (VA-ECMO) and hemostatic support were instituted. With increasing vasoactive requirements, the team selected bedside systemic thrombolysis after multidisciplinary consideration of surgical and catheter-based alternatives. Unfractionated heparin was paused at the first 20-mg alteplase infusion at 17:00. Arterial cannulation-site bleeding at 17:20 was treated with compression. The progress note documented that bleeding had stopped by 19:03; despite reduced vasoactive requirements, support dependence persisted. A second 20-mg infusion began at 19:25. Each stage lasted approximately 1 h. Heparin was restarted after the second infusion. Vasopressors were stopped on Day 1 and VA-ECMO was removed on Day 7. Hemoglobin fell from 150 to 117 g/L on Day 0 and reached 75 g/L on Day 8, prompting red-cell transfusion. Major bleeding could not be excluded. The patient was discharged on Day 19; Day 103 imaging showed no obvious residual pulmonary arterial filling defect. This case describes individualized decisions during multimodal care, not a validated alteplase regimen or evidence of its safety.
SN - 2297-055X
ER -